Capital Research Global Investors’s Ocular Therapeutix OCUL Stock Holding History

Capital Research Global Investors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,865,358	Closed	-$27.7M	–	431
2016 Q1	$27.7M	Hold	2,865,358	–	–	0.01%	365
2015 Q4	$26.8M	Buy	2,865,358 +21,878	+0.8%	+$236K	0.01%	368
2015 Q3	$40M	Hold	2,843,480	–	–	0.01%	355
2015 Q2	$59.8M	Buy	2,843,480 +760,280	+36%	+$18.8M	0.02%	333
2015 Q1	$87.5M	Buy	2,083,200 +1,162,200	+126%	+$38.2M	0.03%	309
2014 Q4	$21.7M	Hold	921,000	–	–	0.01%	393
2014 Q3	$13.8M	Buy	+921,000	New	+$13.6M	﹤0.01%	400

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PGCM

Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

Capital Research Global Investors's OCUL Position: Q2 2016 in Review

Capital Research Global Investors sold out of Ocular Therapeutix (OCUL) in Q2 2016, closing a stake of 2,865,358 shares — an estimated $27.7M sold.

Capital Research Global Investors first reported a position in OCUL in Q3 2014 and held it in 7 quarters. The position peaked at $87.5M in Q1 2015. 75 funds tracked by Wall St. Rank hold OCUL as of Q2 2016.

Capital Research Global Investors reported no remaining Ocular Therapeutix position as of Q2 2016 after selling out during the quarter.
Capital Research Global Investors sold 2,865,358 Ocular Therapeutix shares in Q2 2016, an estimated $27.7M.
Capital Research Global Investors first reported a position in Ocular Therapeutix in Q3 2014 and held it in 7 quarters.
Capital Research Global Investors's Ocular Therapeutix position peaked at $87.5M in Q1 2015.
75 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2016.

Based on Capital Research Global Investors's 13F filing for Q2 2016, filed 15 Aug 2016.